Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19836880 | 1.00 | MAPT (0.34) | MAPTALDH1A1KDM4ENLRP3SMN1; SMN2 | |
| SCHEMBL20187610 | 0.78 | MAPT (0.41) | MAPTALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL20187609 | 0.78 | MAPT (0.41) | MAPTALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL25222326 | 0.75 | TSHR (0.40) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL29136923 | 0.71 | CA12 (0.41) | MAPTALDH1A1KDM4ENLRP3SMN1; SMN2 | |
| SCHEMBL24149776 | 0.71 | CA12 (0.41) | MAPTALDH1A1KDM4ENLRP3SMN1; SMN2 | |
| SCHEMBL15174136 | 0.69 | HSD17B10 (0.39) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL13208839 | 0.67 | HSD17B10 (0.45) | MAPTALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL7377051 | 0.66 | RECQL (0.53) | MAPT | |
| SCHEMBL7377043 | 0.66 | RECQL (0.53) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115605481-A | Compounds as kinase inhibitors | 重庆复尚源创医药技术有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| EP-3224248-B1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-107207441-B | Protein kinase inhibitors | 上海复尚慧创医药研究有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10328060-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | AKT1, PIK3CA, AKT3 | MAPT 2101/4885ALDH1A1 4555/4885KDM4E 2650/4885 |
| US-10328060-B2 | Certain protein kinase inhibitors | AKT1, PIK3CA, AKT3 | MAPT 2101/4885ALDH1A1 4555/4885KDM4E 2650/4885 |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, PIK3CB | MAPT 1343/4885ALDH1A1 4698/4885KDM4E 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.